191 related articles for article (PubMed ID: 31066013)
21. Antifungal prophylaxis in liver transplantation: a systematic review and network meta-analysis.
Evans JD; Morris PJ; Knight SR
Am J Transplant; 2014 Dec; 14(12):2765-76. PubMed ID: 25395336
[TBL] [Abstract][Full Text] [Related]
22. Invasive fungal infections following liver transplantation: incidence, risk factors, survival, and impact of fluconazole-resistant Candida parapsilosis (2003-2007).
Raghuram A; Restrepo A; Safadjou S; Cooley J; Orloff M; Hardy D; Butler S; Koval CE
Liver Transpl; 2012 Sep; 18(9):1100-9. PubMed ID: 22577087
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of anti-fungal agents for invasive fungal infection prophylaxis in liver transplant recipients: A network meta-analysis.
Liu Y; Lan C; Qin S; Qin Z; Zhang Z; Zhang P; Cao W
Mycoses; 2022 Oct; 65(10):906-917. PubMed ID: 35899464
[TBL] [Abstract][Full Text] [Related]
24. Safety and efficacy of micafungin for prophylaxis against invasive fungal infections in Japanese patients undergoing hematopoietic stem cell transplantation: Results of a post-marketing surveillance study.
Kobayashi C; Hanadate T; Niwa T; Hirano Y; Yoshiyasu T; So M; Matsui K
J Infect Chemother; 2015 Jun; 21(6):438-43. PubMed ID: 25749360
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant.
Hiemenz J; Cagnoni P; Simpson D; Devine S; Chao N; Keirns J; Lau W; Facklam D; Buell D
Antimicrob Agents Chemother; 2005 Apr; 49(4):1331-6. PubMed ID: 15793107
[TBL] [Abstract][Full Text] [Related]
26. A targeted fungal prophylaxis protocol with static dosed fluconazole significantly reduces invasive fungal infection after liver transplantation.
Jorgenson MR; Descourouez JL; Marka NA; Leverson GE; Smith JA; Andes DR; Fernandez LA; Foley DP
Transpl Infect Dis; 2019 Oct; 21(5):e13156. PubMed ID: 31390109
[TBL] [Abstract][Full Text] [Related]
27. Invasive Fungal Infection After Lung Transplantation: Epidemiology in the Setting of Antifungal Prophylaxis.
Baker AW; Maziarz EK; Arnold CJ; Johnson MD; Workman AD; Reynolds JM; Perfect JR; Alexander BD
Clin Infect Dis; 2020 Jan; 70(1):30-39. PubMed ID: 30801642
[TBL] [Abstract][Full Text] [Related]
28. Micafungin as antifungal prophylaxis in recipients of allogeneic hematopoietic stem cell transplantation: results of different dosage levels in clinical practice.
Langebrake C; Rohde H; Lellek H; Wolschke C; Kröger NM
Clin Transplant; 2014 Mar; 28(3):286-91. PubMed ID: 24479680
[TBL] [Abstract][Full Text] [Related]
29. An open-label trial of the prophylactic administration of voriconazole in patients who undergo allogeneic hematopoietic stem cell transplantation: study protocol.
Kunitomi A; Hasegawa Y; Hashimoto H; Saito AM; Iida H
Nagoya J Med Sci; 2018 Nov; 80(4):591-595. PubMed ID: 30587873
[TBL] [Abstract][Full Text] [Related]
30. Randomized controlled trial of oral itraconazole solution versus intravenous/oral fluconazole for prevention of fungal infections in liver transplant recipients.
Winston DJ; Busuttil RW
Transplantation; 2002 Sep; 74(5):688-95. PubMed ID: 12352887
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of echinocandins versus triazoles for the prophylaxis and treatment of fungal infections: a meta-analysis of RCTs.
Wang JF; Xue Y; Zhu XB; Fan H
Eur J Clin Microbiol Infect Dis; 2015 Apr; 34(4):651-9. PubMed ID: 25502737
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of targeted versus universal prophylaxis for the prevention of invasive fungal infections following lung transplantation.
Linder KA; Kauffman CA; Patel TS; Fitzgerald LJ; Richards BJ; Miceli MH
Transpl Infect Dis; 2021 Feb; 23(1):e13448. PubMed ID: 33448560
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of micafungin as an empirical therapy for invasive fungal infections in patients with hematologic disorders: a multicenter, prospective study.
Yamaguchi M; Kurokawa T; Ishiyama K; Aoki G; Ueda M; Matano S; Takami A; Yamazaki H; Sawazaki A; Yamauchi H; Yoshida T; Nakao S
Ann Hematol; 2011 Oct; 90(10):1209-17. PubMed ID: 21695388
[TBL] [Abstract][Full Text] [Related]
34. Breakthrough invasive fungal infections in liver transplant recipients exposed to prophylaxis with echinocandins vs other antifungal agents: A systematic review and meta-analysis.
Gatti M; Rinaldi M; Ferraro G; Toschi A; Caroccia N; Arbizzani F; Raschi E; Poluzzi E; Pea F; Viale P; Giannella M
Mycoses; 2021 Nov; 64(11):1317-1327. PubMed ID: 34387004
[TBL] [Abstract][Full Text] [Related]
35. Micafungin versus amphotericin B lipid complex for the prevention of invasive fungal infections in high-risk liver transplant recipients.
Sun HY; Cacciarelli TV; Singh N
Transplantation; 2013 Sep; 96(6):573-8. PubMed ID: 23842191
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of a primary antifungal prophylaxis protocol for preventing invasive mold infections after allogeneic hematopoietic stem cell transplantation.
Herity LB; Cruz OA; Aziz MT
J Oncol Pharm Pract; 2022 Jun; 28(4):794-804. PubMed ID: 33906508
[TBL] [Abstract][Full Text] [Related]
37. Prophylactic fluconazole in liver transplant recipients. A randomized, double-blind, placebo-controlled trial.
Winston DJ; Pakrasi A; Busuttil RW
Ann Intern Med; 1999 Nov; 131(10):729-37. PubMed ID: 10577295
[TBL] [Abstract][Full Text] [Related]
38. Antifungal prophylaxis among allogeneic hematopoietic stem cell transplant recipients: current issues and new agents.
Strasfeld L; Weinstock DM
Expert Rev Anti Infect Ther; 2006 Jun; 4(3):457-68. PubMed ID: 16771622
[TBL] [Abstract][Full Text] [Related]
39. Antifungal prophylaxis with micafungin in patients treated for childhood cancer.
Kusuki S; Hashii Y; Yoshida H; Takizawa S; Sato E; Tokimasa S; Ohta H; Ozono K
Pediatr Blood Cancer; 2009 Oct; 53(4):605-9. PubMed ID: 19533659
[TBL] [Abstract][Full Text] [Related]
40. Choosing Optimal Antifungal Agents To Prevent Fungal Infections in Nonneutropenic Critically Ill Patients: Trial Sequential Analysis, Network Meta-analysis, and Pharmacoeconomic Analysis.
Wang Y; Xie J; Xing Y; Chen L; Li Y; Meng T; Dong W; Wang X; Dong Y
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28993334
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]